The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial
Abstract
359 eligible children with acute myeloid leukaemia (AML) entered the MRC AML 10 trial between May 1988 and March 1995. Patients received four courses of intensive induction and consolidation chemotherapy, with or without subsequent autologous (A‐BMT) or allogeneic (allo‐BMT) bone marrow transplant. There were randomized comparisons of thioguanine versus etoposide in induction and of A‐BMT versus not. Allo‐BMT was recommended for patients with a HLA‐matched sibling and was evaluated by donor versus no donor comparison. The complete remission rate was 92%. In first remission there were 20 deaths during consolidation chemotherapy and 11 after BMT (8/61 allo‐BMTs, 1/60 A‐BMTs and 2/4 matched unrelated donor transplants). The relapse rate was low, decreasing from 26% in the first year to 2% in the fourth. Long‐term outcome was excellent with survival at 7 years from entry of 56% and event‐free survival of 48%. There were no significant differences between thioguanine and etoposide, whereas both A‐BMT and allo‐BMT reduced relapse risk but did not produce a significant survival benefit. It appears that over half the children entered into AML 10 are cured, a result which compares favourably with other reported series. We conclude that four courses of intensive chemotherapy are an effective approach to the treatment of paediatric AML, which avoids the acute toxicity and long‐term side‐effects of BMT and also avoids the need for prolonged maintenance therapy or cranial irradiation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241205 · Cited by 1,404
Cardiac Toxicity 4 to 20 Years After Completing Anthracycline Therapy
Steinherz, L. J. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470120074036 · Cited by 989
Burnett, A. K., Goldstone, A. H., Stevens, R. M., Hann, I. M., Rees, J. K., Gray, R. G., & Wheatley, K. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09214-3 · Cited by 563
Self-citationMantel, N., & Byar, D. P. (1974) · Journal of the American Statistical Association · doi:10.1080/01621459.1974.10480131 · Cited by 445
Speyer, J. L., Green, M. D., Kramer, E., Rey, M., Sanger, J., Ward, C., Dubin, N., Ferrans, V., Stecy, P., Zeleniuch-Jacquotte, A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809223191203 · Cited by 356
Woods, W., Kobrinsky, N., Buckley, J., Lee, J., Sanders, J., Neudorf, S., Gold, S., Barnard, D., DeSwarte, J., Dusenbery, K., et al. (1996) · Blood · doi:10.1182/blood.v87.12.4979.bloodjournal87124979 · Cited by 329
Principal results of the Medical Research Council’s 8th acute myeloid leukaemia trial
REES, J. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92674-7 · Cited by 320
Hann, I. M., Stevens, R. F., Goldstone, A. H., Rees, J. K. H., Wheatley, K., Gray, R. G., & Burnett, A. K. (1997) · Blood · doi:10.1182/blood.v89.7.2311 · Cited by 297
Self-citationRavindranath, Y., Yeager, A. M., Chang, M. N., Steuber, C. P., Krischer, J. P., Graham‐Pole, J., Carroll, A. J., Inoue, S., Camitta, B. M., & Weinstein, H. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605303342203 · Cited by 250
Wexler, L. H., Andrich, M. P., Venzon, D., Berg, S. L., Weaver-McClure, L., Chen, C. C., Dilsizian, V, Avila, N., Jarosinski, P., Balis, F. M., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.362 · Cited by 224
Cited by
Lowenberg, B., Downing, J. R., & Burnett, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909303411407 · Cited by 1,217
Rubnitz, J. E., Inaba, H., Ribeiro, R. C., Pounds, S., Rooney, B., Bell, T., Pui, C.-H., & Leung, W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.4590 · Cited by 649
Rubnitz, J. E., Inaba, H., Dahl, G., Ribeiro, R. C., Bowman, W. P., Taub, J., Pounds, S., Razzouk, B. I., Lacayo, N. J., Cao, X., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70090-5 · Cited by 584
Creutzig, U., van den Heuvel-Eibrink, M. M., Gibson, B., Dworzak, M. N., Adachi, S., de Bont, E., Harbott, J., Hasle, H., Johnston, D., Kinoshita, A., et al. (2012) · Blood · doi:10.1182/blood-2012-03-362608 · Cited by 577
Gamis, A. S., Alonzo, T. A., Meshinchi, S., Sung, L., Gerbing, R. B., Raimondi, S. C., Hirsch, B. A., Kahwash, S. B., Heerema-McKenney, A., Winter, L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.3628 · Cited by 486
Metadata
- Authors
- Stevens, R. F., Hann, I. M., Wheatley, K., Gray, R. G., & Party, O. B. O. T. M. C. L. W.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 1998-04
- Volume
- 101
- Issue
- 1
- Pages
- 130-140
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2040336044
- Cited by
- 309
- References
- 12
- FWCI
- 11.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial. https://app.cochat.ai/papers/10.1046/j.1365-2141.1998.00677.x
- The paper
- Stevens, R. F., Hann, I. M., Wheatley, K., Gray, R. G., & Party, O. B. O. T. M. C. L. W. (1998). Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial. British Journal of Haematology. https://doi.org/10.1046/j.1365-2141.1998.00677.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.